Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies

BackgroundThe National Psoriasis Foundation (NPF) published treatment targets for US patients with plaque psoriasis. However, data are lacking on how well existing therapies help achieve these goals.ObjectiveTo examine the ability of an interleukin 17 inhibitor, ixekizumab, in achieving targets.MethodsPost hoc analysis was performed pooled from 4 phase III clinical trials assessing ixekizumab psoriasis: UNCOVER-1, -2, and -3 IXORA-S trial. Treatment response evaluated using NPF-defined acceptable (affected body surface area [BSA] 3% or less BSA improvement 75% higher at 12 weeks treatment) target (BSA 1% every 6 months thereafter).ResultsIn UNCOVER (n = 2701), rates week were 73.9% 51.8% 80 mg 2 weeks, 35.7% 14.9% etanercept 50 mg, 3.0% 0.6% placebo, respectively. In trial 302), significantly versus ustekinumab (acceptable 68.4% vs 38.6%, P < .0001; 50.7% 24.1%, .0001).LimitationsData controlled studies may not reflect real-world practice.ConclusionThe majority treated achieved NPF, patient-centered targets. The goals. To Post thereafter). .0001). Data practice.